Literature DB >> 7197193

Immunochemical studies of DNA modified by cis-dichlorodiammineplatinum(II) in vivo and in vitro.

B Malfoy, B Hartmann, J P Macquet, M Leng.   

Abstract

Two rabbits were immunized with native DNA modified in vitro by cis-dichlorodiammineplatinum(II) (cis-Pt). The interactions between the antiserum and several natural and synthetic nucleic acids were studied primarily by radioimmunoassays. Native DNA's modified by platinum compounds with labile groups in the cis position are recognized by the antiserum. No cross-reaction is found with native DNA's substituted by other platinum compounds [trans-dichlorodiammineplatinum(II), cis-diamminotetrachloroplatinum(IV), and chlorodiethylenetriamminoplatinum(II)] and with natural and synthetic modified polyribonucleotides. cis-Pt-modified oligodeoxyribonucleotides and enzymatically hydrolyzed cis-Pt-modified native DNA do not bind to the antiserum. cis-Pt-modified double-stranded synthetic polydeoxyribonucleotides are either hardly recognized or not recognized at all. The antiserum recognized a modified double-stranded helix in DNA which is not formed in several modified synthetic DNA's and RNA's. At least two different antigenic determinants are present in cis-Pt-modified DNA at a ratio of cis-Pt to bases equal to 0.05. Finally, the antiserum does not react with in vivo cis-Pt-modified DNA.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7197193

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Nucleotide sequence of an heterochromatic segment recognized by the antibodies to Z-DNA in fixed metaphase chromosomes.

Authors:  B Malfoy; N Rousseau; N Vogt; E Viegas-Pequignot; B Dutrillaux; M Leng
Journal:  Nucleic Acids Res       Date:  1986-04-25       Impact factor: 16.971

2.  Monoclonal antibodies to DNA modified with cis- or trans-diamminedichloroplatinum(II).

Authors:  W I Sundquist; S J Lippard; B D Stollar
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

3.  Pharmacokinetics in experimental and clinical chemotherapy.

Authors:  P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Reactivity of monofunctional cis-platinum adducts as a function of DNA sequence.

Authors:  J M Malinge; M Leng
Journal:  Nucleic Acids Res       Date:  1988-08-11       Impact factor: 16.971

Review 5.  Platinum antitumour agents: a review of (bio)analysis.

Authors:  T J Hodes; W J Underberg; G Los; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

6.  Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro.

Authors:  M C Poirier; S J Lippard; L A Zwelling; H M Ushay; D Kerrigan; C C Thill; R M Santella; D Grunberger; S H Yuspa
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

7.  Base sequence-independent distorsions induced by interstrand cross-links in cis-diamminedichloroplatinum (II)-modified DNA.

Authors:  J M Malinge; C Pérez; M Leng
Journal:  Nucleic Acids Res       Date:  1994-09-25       Impact factor: 16.971

8.  Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides.

Authors:  P M Terheggen; B G Floot; E L Lempers; O van Tellingen; A C Begg; L den Engelse
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  Characterization of the ternary complexes formed in the reaction of cis-diamminedichloroplatinum (II), ethidium bromide and nucleic acids.

Authors:  J M Malinge; A Schwartz; M Leng
Journal:  Nucleic Acids Res       Date:  1987-02-25       Impact factor: 16.971

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.